NCT01933958View on ClinicalTrials.gov

Regorafenib Post-marketing Surveillance in Japan

CompletedOBSERVATIONAL
Enrollment

72

Participants

Timeline

Start Date

September 4, 2013

Primary Completion Date

March 29, 2021

Study Completion Date

October 29, 2021

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Regorafenib (Stivarga, BAY73-4506)

The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.

Trial Locations (1)

Unknown

Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01933958 - Regorafenib Post-marketing Surveillance in Japan | Biotech Hunter | Biotech Hunter